Compare PLSE & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | ABCL |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2016 | 2020 |
| Metric | PLSE | ABCL |
|---|---|---|
| Price | $13.86 | $2.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $22.00 | $7.75 |
| AVG Volume (30 Days) | 162.7K | ★ 5.0M |
| Earning Date | 02-19-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $86,000.00 | ★ $35,325,000.00 |
| Revenue This Year | N/A | $25.45 |
| Revenue Next Year | $1,057.59 | $10.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.17 |
| 52 Week Low | $12.56 | $1.89 |
| 52 Week High | $25.00 | $6.52 |
| Indicator | PLSE | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 26.80 |
| Support Level | $13.44 | $3.92 |
| Resistance Level | $15.25 | $3.69 |
| Average True Range (ATR) | 0.80 | 0.30 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 23.10 | 2.38 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.